Deere & Company vs Zoetis Inc — how do they compare? Deere & Company trades at $652.58 (market cap $175.95B), while Zoetis Inc trades at $73.02 (market cap $30.20B). The key difference: Deere & Company is far larger — about 5.8× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Deere & Company for 75 Days and Zoetis Inc for 70 Days on average.
| DE | ZTS | |
|---|---|---|
Market Cap | $175.95B | $30.20B |
Volume | 1,387,231 | 6,175,327 |
Sector | Industrials | Health |
52-Week High | $709.48 | $147.53 |
52-Week Low | $439.11 | $69.09 |
Typical Hold Time | 75 Days | 70 Days |
Enterprise Value | $229.85B | $37.76B |
Dividend Yield | 0.99% | 2.9% |
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $656.87, down 3.8% on the day, reflecting near-term pressure amid a broader bearish technical signal. The stock has demonstrated strong earnings momentum, beating estimates in the last three quarters, but faces headwinds from declining revenue and net income margins. Recent news highlights the company's focus on AI-driven agricultural solutions to counter cyclical downturns, while analyst consensus remains divided with a price target of $731.20 suggesting potential upside from current levels.
The outlook for DE is mixed; solid profitability metrics and consistent cash flow generation support the investment case, but cyclical exposure to agriculture equipment demand and elevated valuation ratios pose risks. Earnings growth and successful execution of technology initiatives are key catalysts for outperformance, though macroeconomic volatility could dampen near-term returns.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed quarterly earnings performance - beating expectations in Q2 2026 but missing in Q1. Strong fundamentals persist with 71.67% gross margins and 27.69% net income margins, though recent headwinds include U.S. companion animal market weakness and increased competition in key therapeutic areas. The company maintains robust cash flow generation with $2.9 billion from operations in 2025.
Despite near-term pressures, ZTS presents value opportunity with attractive valuation at 11.67 P/E ratio and consensus price target of $87.33 suggesting 22% upside. Risks include ongoing competitive pressures and U.S. market softness, but industry-leading profitability and international growth provide stability. Analyst sentiment remains positive with no sell ratings among 32 covering firms, though technical indicators suggest cautious near-term positioning.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →